Review article

https://doi.org/10.2478/acph-2023-0002

Intensive critical care and management of asthmatic and smoker patients in COVID-19 infection

DONGMING LU ; Department of Pulmonary and Critical Care Medicine, Jinling Hospital Nanjing University School of Medicine, Nanjing, Jiangsu, 210000, China
OBAID YAQOOB ; Department of Pharmacology, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (An Autonomous College), Ropar, Punjab, 140111, India
MANISH KUMAR orcid.org/0000-0001-6697-544X ; Chitkara College of Pharmacy, Chitkara University, Punjab, 140401, India; Department of Neurosurgery, College of Medicine, Penn State Health Milton S. Hershey Medical Center, The Pennsylvania State University, Pennsylvania 17033-0850, USA
AJAY SINGH KUSHWAH orcid.org/0000-0003-0559-7670 ; Department of Pharmacology, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (An Autonomous College), Ropar, Punjab, 140111, India
RAHUL KUMAR SHARMA ; Department of Pharmacology, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (An Autonomous College), Ropar, Punjab, 140111, India
DEVINDER KUMAR ; Department of Pharmacology, Amar Shaheed Baba Ajit Singh Jujhar Singh Memorial College of Pharmacy, Bela (An Autonomous College), Ropar, Punjab, 140111, India
YOGENDRA MAVAI ; IPS College of Pharmacy, Shivpuri Link Road Gwalior, M.P., 474001, India
RUKAIYA KHAN ; Abhilashi College of Pharmacy, Nerchowk Mandi, H.P., 175008, India

Abstract

This century's most serious catastrophe, COVID-19, has been dubbed "the most life-threatening disaster ever". Asthmatic persons are even more prone to COVID-19's complex interplay with the underlying inflammatory condition. In order to protect themselves against COVID-19, asthmatic patients must be very vigilant in their usage of therapeutic techniques and drugs (e.g., bronchodilators, 5-lipoxygenase inhibitors), which may be accessed to deal with mild, moderate, and severe COVID-19 indications. People with asthma may have more severe COVID-19 symptoms, which may lead to a worsening of their condition. Several cytokines were found to be elevated in the bronchial tracts of patients with acute instances of COVID-19, suggesting that this ailment may aggravate asthma episodes by increasing inflammation. The intensity of COVID-19 symptoms is lessened in patients with asthma who have superior levels of T-cells. Several antibiotics, antivirals, antipyretics, and anti-inflammatory drugs have been suggested to suppress COVID-19 symptoms in asthmatic persons. Furthermore, smokers are more likely to have aggravated repercussions in COVID-19 infection. Being hospitalized to critical care due to COVID-19, needing mechanical breathing, and suffering from serious health repercussions, are all possible outcomes for someone who has previously smoked. Smoking damages airways and alveoli, which significantly raises the risk of COVID-19-related health complications. Patients with a previous record of smoking are predisposed to severe COVID-19 disease symptoms that essentially require a combination of bronchodilators, mucolytics, antivirals, and antimuscarinic drugs, to cope with the situation. The present review discusses the care and management of asthmatic and smoker patients in COVID-19 infection.

Keywords

COVID-19; asthma; smoking; critical care; SARS-CoV-2

Hrčak ID:

281778

URI

https://hrcak.srce.hr/281778

Publication date:

31.3.2023.

Visits: 1.079 *